Be involved in funding an exciting new technology for clinical medicine

Be involved in funding an exciting new technology for clinical medicine Brian Tait, Chief Scientific Officer at Haplomic Technologies Pty Ltd, calls for public support to fund exciting groundbreaking technology for assigning phase to multiple mutations – a unique contribution to clinical medicine. New groundbreaking technology for assigning phase to multiple mutations – a unique contribution to clinical medicine. The method can be used in one of two ways. In cases where alleles have been well established and sequenced, it can be used to determine haplotypes such as the HLA system. In cases where alleles have been defined by linkage disequilibrium (LD) between single nucleotide polymorphisms (SNPs), by next-generation sequencing (NGS) or by third-generation sequencing, it can be used to determine both alleles present in an individual by the sequencing of both chromosomes separately, with theoretical 100% accuracy.